HiSiaddi is an innovative foreign trade service provider driven by both technology transformation and export business. We have established a "1+2+3+4=1" service system and can supply alpha lipoic acid sourced directly from multiple well-known original manufacturers.
As a foreign trade enterprise with R&D capabilities, HiSiaddi has conducted multiple rounds of on-site inspections of alpha-lipoic acid manufacturers and holds objective, in-depth understanding of different brands. We regularly analyze various domestic alpha-lipoic acid manufacturers for clients to help them select matching raw material products. Below is a brand selection and evaluation case.
Contact HiSiaddi customer service for detailed comparative analysis of brands and product grades.
The buyer is MEDIFARM, a premium German medical pharmaceutical company headquartered in Nuremberg, Germany. With 29 years of expertise in high-end dietary supplements, medical prescription raw materials for diabetic care and anti-aging medical beauty raw materials across German-speaking regions including Germany, Austria and Switzerland, its products are sold in premium dm cosmetic counters in Germany, nutrition departments of private specialist hospitals and organic health supermarkets in Switzerland. Raw materials comply with European EP Pharmacopoeia, EFSA food raw material access specifications, REACH regulations and Germany’s LFGB food safety act. Its three core finished products include soft capsules for diabetic nerve repair, oral anti-aging sustained-release hard capsules and weakly acidic antioxidant medical beauty essences, targeting middle and high-net-worth consumer groups in Europe. The group maintains stable annual alpha-lipoic acid procurement of 24 tons, historically sourcing pharmacopoeia-grade alpha-lipoic acid from BASF (Germany) and Kyowa Chemical (Japan) for over a decade.
Driven by price hikes of local European chemical raw materials, extended lead times and elevated minimum order thresholds for customized samples from original manufacturers, the group launched a localization substitution plan for Chinese raw materials in 2025.
Core client pain points: With decades of experience serving European markets, the enterprise lacked familiarity with the domestic Chinese alpha-lipoic acid brand hierarchy, segmented product grades from each manufacturer, process differences, applicable scenarios and certification systems. Independent email inquiries to five large domestic manufacturers yielded product data sheets with inconsistent parameter standards and disorganized product grades. Five distinct trial samples received for testing triggered three major production failures: filling mesh clogging, precipitation during essence compounding and excessive oxidative deterioration in accelerated finished product storage trials. The R&D department suspended sourcing progress for nearly three months. To avoid mass production scrapping risks from mismatched raw materials and failure of end-product German pharmaceutical inspections, the client fully entrusted HiSiaddi to leverage our full industrial chain brand database for neutral horizontal evaluation and comparison of leading domestic manufacturers, decompose advantages and disadvantages of mainstream product grades, and screen two mid-to-high-end manufacturers and three finalized product grades matching the client’s three end-product production workflows, ultimately finalizing a procurement plan.
Mandatory client sourcing thresholds (mid-to-high-end standard, excluding low-grade industrial raw materials): Raw materials are divided into three grades corresponding to three application scenarios with distinct indicators:
1. DL pharmacopoeia-grade alpha-lipoic acid for soft capsule filling: HPLC purity ≥99.0%, D90 ≤22μm, angle of repose ≤29°.
2. Modified encapsulated grade for sustained-release medical dietary capsules: total active ingredient attenuation ≤4% under 24-month room-temperature storage.
3. High-purity refined grade for medical beauty essence stock solutions: single organic solvent residual <0.5ppm, lead and arsenic heavy metals below EP Pharmacopoeia limits. All product lines must be accompanied by full export compliance certifications including EP/USP English COA, LFGB, KOSHER and REACH registration documents.
The client independently contacted five large-scale domestic alpha-lipoic acid manufacturers: Jiangsu Caiwei Bio, Shandong Xinhua Pharmaceutical, Shaanxi Chenming Bio, Hebei Hongtao Bio and Hubei Haijia Bio. All five are legally certified large-scale manufacturers offering food-grade, pharmaceutical pharmacopoeia-grade and customized modified grades, yet all follow standard industry sales practices: manufacturers only elaborate on their own product advantages, production capacity, quotations and certifications, avoiding discussion of competitors’ strengths and only vaguely stating "different manufacturers adopt distinct process routes with varied applicable products" when asked about rival brands, concealing competitor process highlights, grade segmentation and inherent weaknesses. This created four major sourcing blind spots for the client:
1. Unclear brand tier classification: All five manufacturers claimed to be domestic benchmarks for premium pharmacopoeia-grade raw materials, leaving the client unable to distinguish first-tier pharmaceutical API manufacturers, second-tier fine modification specialized enterprises and third-tier mass-produced low-cost food-grade suppliers – mistakenly benchmarking generic food-grade products against European pharmacopoeia procurement standards.
2. Lack of grade classification awareness: Each brand offers four core grades: basic national standard grade, EP pharmacopoeia export grade, microencapsulated modified grade and high-purity refined grade. Manufacturers adopt self-defined trade names with no unified national standard coding, making it impossible for the client to distinguish purity, powder performance and modification differences solely based on product names.
3. Ambiguous applicable scenarios: Grade A from Brand X is suitable for soft capsules but incompatible with weakly acidic essence stock solutions, while modified grades from Brand Y perform well in essences yet feature overly coarse powder unsuitable for automatic filling. All manufacturers falsely claim their products are universally applicable to all scenarios while concealing product limitations, leading to repeated trial failures during client equipment testing.
4. Uninterpretable pricing logic: Raw materials labeled with identical 99% purity exhibited a 28% price gap across five manufacturers. Each manufacturer explained pricing based on raw material costs and process investment, yet the client could not identify price differences stemming from synthetic routes, post-production refining, powder modification and certification investment, mistakenly assuming low-priced products also meet EP Pharmacopoeia standards.
Testing results of the five trial samples were highly inconsistent: two grades exceeded particle size limits and clogged filling meshes, one uncoated raw material turned brown after 45 days of accelerated oxidation testing, and one insufficiently refined grade formed precipitation during essence compounding. Lacking information support on China’s raw material industry, the client’s R&D team stalled sourcing and formally appointed HiSiaddi to conduct neutral brand evaluation and selection.
Drawing on years of export technical reserves and brand databases for alpha-lipoic acid, HiSiaddi adopted a neutral third-party perspective independent of single-manufacturer sales orientation. We analyzed five major manufacturers across seven dimensions: brand positioning, core processes, mainstream available grades, product strengths, inherent limitations, applicable end-product categories and compliance certifications, compiling a full neutral evaluation report delivered to the German client without bias toward any manufacturer. Detailed breakdowns of the five brands are as follows:
Brand Positioning: Benchmark high-purity alpha-lipoic acid enterprise in the Yangtze River Delta, specializing in European and American export pharmacopoeia-grade raw materials for medical dietary and high-end medical beauty sectors. Equipped with three exclusive clean production lines for chiral separation, low-temperature jet milling and cyclodextrin encapsulation, products aligned with USP/EP Pharmacopoeia standards. Three mainstream available grades: ① AL-DL99EP: Generic racemic DL pharmacopoeia-grade, HPLC ≥99.2%, conventional crystalline powder – basic export grade. ② AL-F16 ultrafine powder modified grade: Liquid nitrogen low-temperature milled with D90=15–18μm, trace silicon dioxide flow aid added – optimized for fully automatic soft capsule filling. ③ AL-CDP encapsulated refined grade: β-cyclodextrin surface encapsulation with 6-month accelerated attenuation ≤2.8% under 40℃, deep impurity removal – suitable for sustained-release capsules and weakly acidic essence stock solutions. Strengths: Strict purity control, ultra-low impurity residuals, customizable refined powder performance, full product line certified with LFGB, KOSHER and USP certifications, stable long-term supplier to leading European and American health enterprises. Limitations: Minimum mass production order of 300kg; standard spot quotations 12% higher than industry average, no obvious price advantage for large-tonnage bulk procurement. Applicable Scenarios: Premium soft capsules, medical sustained-release dietary supplements, full-spectrum medical beauty essence products.
Brand Positioning: China’s earliest industrialized mass producer of alpha-lipoic acid, a listed pharmaceutical group with full industrial chain cost advantages focused on large-volume standardized EP pharmacopoeia-grade raw materials, core supplier to domestic pharmaceutical formulation factories. Two mainstream grades: ① XH-DL99USP: Standardized uncoated pharmacopoeia powder, HPLC ≥99.0%, conventional milling particle size 50–80μm – bulk spot goods. ② XH-FOOD98: National standard food-grade with 98.0% purity, targeting domestic health product markets without dedicated EP testing. Strengths: Massive production capacity, stable supply chain, prominent price advantages for large-batch procurement, full GMP workshop control and complete REACH registration. Limitations: No proprietary ultrafine milling or encapsulation modification workshops; powder and stability modification requires outsourced processing; minimum trial order threshold of 1 ton for small batches; uncoated raw materials cannot be directly used in weakly acidic essence stock solutions. Applicable Scenarios: Large-volume ordinary soft capsules, solid health supplements.
Brand Positioning: All-round raw material enterprise in Northwest China with product lines spanning low-grade industrial-grade, mid-tier food-grade and limited premium pharmacopoeia-grade products, supplying both domestic markets and Southeast Asian export channels. Mainstream grades: CM-DL97 generic food grade, CM-DL99 basic pharmaceutical grade. Strengths: Comprehensive product portfolio, flexible minimum orders (samples available at 10kg), low quotations for small and medium batches. Limitations: No stable mass production lines for premium pharmacopoeia grades; modified products rely heavily on outsourced processing; heavy metal and solvent residuals in partial batches only meet national standard minimum limits, unable to consistently satisfy stringent European EP thresholds. Applicable Scenarios: Mid-tier domestic health supplements, low-cost dietary raw materials for Southeast Asian markets; incompatible with German high-end medical dietary access requirements.
Brand Positioning: Large-scale producer of low-cost raw materials targeting domestic feed additives, ordinary health supplements and low-end export markets in India and Southeast Asia. Mainstream grades: HT-DL96 generic national standard grade, HT-DL98 food grade. Strengths: Industry-low quotations, million-ton annual production capacity, abundant spot inventory. Limitations: No dedicated EP/USP quality control systems or clean refining workshops; solvent and heavy metal indicators only meet minimum national standards, failing German LFGB sampling inspections. Applicable Scenarios: Low-end civilian health supplements, feed additives; inconsistent with the client’s mid-to-high-end procurement standards.
Brand Positioning: Specialized in customized liquid liposome alpha-lipoic acid with limited solid powder production capacity, targeting premium cosmetic raw material markets. Mainstream grades: HJ-LIPO liquid encapsulated alpha-lipoic acid, HJ-DL99 refined powder. Strengths: Industry-leading liquid modification technology with excellent compatibility for essence stock solutions. Limitations: Small-scale solid powder mass production with extended lead times, single-category powder products lacking dedicated ultrafine filling grades, insufficient supply capacity for large-volume soft capsule raw material orders. Applicable Scenarios: Medical beauty liquid essences; unable to fully support the client’s three-category finished product production lines.
HiSiaddi compiled a horizontal comparison table of the five brands, marking compatibility levels, risk points and quotation ranges for each brand grade against the client’s three product lines, clearly distinguishing tiers: first-tier premium pharmaceutical manufacturers (Caiwei, Xinhua), second-tier mid-range comprehensive suppliers (Chenming), third-tier low-cost mass producers (Hongtao) and niche specialized manufacturers (Haijia). This fully clarified domestic brand grading and grade differentiation for the German client.
Based on neutral evaluation data and production conditions of the client’s soft capsule, sustained-release capsule and medical beauty essence lines, we eliminated Hebei Hongtao (substandard grade), Shaanxi Chenming (unstable quality) and Hubei Haijia (incomplete product portfolio). Two leading mid-to-high-end manufacturers – Jiangsu Caiwei Bio and Shandong Xinhua Pharmaceutical – were finalized, with three targeted grades selected for segmented procurement. Sourcing logic breakdown below:
1. AL-F16 ultrafine powder modified grade (exclusively for fully automatic soft capsule filling): Tested D90 of 16.2μm, angle of repose 26.8%, perfectly matching parameter requirements of the client’s German imported filling equipment to eliminate mesh clogging and excessive filling weight deviation – meeting annual soft capsule raw material demand of 11 tons.
2. AL-CDP cyclodextrin encapsulated refined grade (shared for sustained-release capsules & weakly acidic medical beauty essences): Deep impurity removal with all single solvent residuals <0.4ppm, total active ingredient attenuation of only 2.6% after 6-month accelerated testing at 40℃. This grade resolves both browning issues during sustained-release capsule storage and precipitation risks of alpha-lipoic acid in acidic essence environments, covering annual demand of 8 tons for sustained-release capsules and essence stock solutions.
This grade features HPLC ≥99.0% with full EP testing compliance and prominent cost advantages for large-volume procurement. The client designated it for mass production inventory of basic standard formulations with an annual procurement volume of 5 tons, serving as a low-cost supplement to primary modified raw materials to reduce overall raw material procurement expenses.
The three finalized grades feature clear segmented application scenarios, fully matching the client’s complete product portfolio while balancing quality compliance, production stability and procurement costs, mitigating supply interruption risks from single-brand reliance.
HiSiaddi coordinated both manufacturers to produce 10kg trial samples per specified grade, unifiedly shipped to MEDIFARM’s R&D laboratory in Nuremberg, Germany for three full tests: soft capsule filling trials, sustained-release accelerated stability testing and essence compounding trials. Caiwei AL-F16 ran 24-hour continuous filling without mesh clogging; AL-CDP yielded clear solutions with zero precipitation or discoloration after 90 days of essence standing; Shandong Xinhua XH-DL99USP met all indicators for basic formulation production. All three grades passed EP Pharmacopoeia and German LFGB testing, and the client issued a written sample qualification confirmation letter.
The client finalized an annual procurement framework for 24 tons delivered in six sea freight shipments to Hamburg Port, including a combined 19 tons of the two Caiwei grades and 5 tons of Shandong Xinhua’s grade. HiSiaddi coordinated third-party SGS pre-shipment testing for each batch, full English compliance documentation preparation, customs declaration and sea freight logistics. Pre-shipment review of COA, SDS and LFGB certifications was mandated to ensure zero barriers during German customs clearance. The first 3.8-ton shipment cleared customs and entered client warehouses within 3 working days upon arrival at port, enabling full-load production across three client lines with zero raw material-related production failures and 0 semi-finished product scrapping rate.
1. The client fully eliminated import sources from BASF (Germany) and Japanese alpha-lipoic acid suppliers, shifting 100% of the annual 24-ton raw material procurement volume to finalized Chinese grades. Comprehensive procurement costs decreased by 21.7%, and sea freight lead times shortened from the original 85 days to 33 days.
2. Building on this neutral brand selection service, the client added customized demand for high-activity R-chiral alpha-lipoic acid for its Austrian sub-brand in 2026, continuing to entrust HiSiaddi with domestic manufacturer screening and process coordination, generating an incremental annual procurement volume of 9 tons.
3. During the R&D phase of the client’s new plant extract effervescent tablet product line, HiSiaddi was commissioned in advance to conduct pre-selection of raw material brands to avoid sourcing risks at an early stage.
China’s alpha-lipoic acid industry exhibits clear brand tier segmentation, with stark gaps in process performance, technical indicators and compliance certifications between premium pharmacopoeia-grade, mid-tier food-grade and low-grade industrial-grade products. Constrained by sales-oriented business models, domestic manufacturers generally only promote their own products while avoiding discussion of competitor strengths. Mid-to-high-end European pharmaceutical enterprises lack information on China’s industrial landscape, and independent sourcing frequently results in mismatched product grades, scrapped trial samples and compliance violations.
Breaking free from the one-way sales promotion model of raw material manufacturers, HiSiaddi adopts a neutral third-party perspective to horizontally decompose full-dimensional information of multiple brands, implementing hierarchical brand and grade screening aligned with the actual production conditions of clients’ end products. Our services help mid-to-high-end European clients break through information barriers regarding Chinese manufacturers and select matching raw materials, while supporting leading domestic mid-to-high-end manufacturers to secure stable long-term repeat large-volume orders from European markets – achieving a win-win situation for both supply and demand sides.
Contact HiSiaddi customer service for detailed comparative analysis of brands and product grades.
+86-13120989737 
info@hisiaddi.com 
English
